The present disclosure is responsive to treatment with anti-CD19 antibodies, chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), small lymphocytic lymphoma (SLL) or acute lymphoblastic leukemia (ALL). A) providing a blood sample obtained from the subject prior to treatment with the anti-CD19 antibody, b) i) peripheral NK cell count, and ii) CD16 on peripheral NK cells. Measuring the level of at least one biomarker in said sample selected from the group consisting of expression levels; c) comparing the level of said at least one biomarker in said sample to a predetermined cutoff level And said at least one biomarker at or above a predetermined cutoff level Level indicates the subject that would benefit from treatment with the anti-CD19 antibody, a method to target. The present disclosure is also directed to methods for selecting patients for treatment according to the above and the use of anti-CD19 antibodies for the treatment of such patients. 【Selection chart】 None
展开▼
